Trial
NCT04551053
To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Incyte Corporation
Collaborators
—
Condition
Myelofibrosis
Intervention
parsaclisib
Why stopped
The study was terminated due to futility.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-10-02